특발성 파킨슨병 환자의 뜸치료 효과

Effect of Moxibustion on Patients with Idiopathic Parkinson's Disease

2004 년 3월 9일부터 5월 15일까지 경희의료원 침구과 외래를 내원하여 8주간 연구과정을 마친 환자 29명의 환자를 관찰하여 뜸치료 전, 후의 파킨슨병 증상의 호전도를 여러 임상 척도를 이용하여 살펴 본 결과를 다음과 같이 보고하는 바이다. 1. UPDRS 점수는 침치료 전, 4주 후, 8주 후 각각 $35.41{\pm}22.98$, $31,93{\pm}23.44$, $30.75{\pm}24.55$로 나타나 통계적으로 매우 유의한 차이가 있었다 (p<0.01). 2. HY stage의 변화는 4주후(p=0.046)에는 유의한 변화가 있으나, 8주후에는 (0.063) 유의한 변화가 없었다. 3. Schwab과 England에 의한 ADL의 변화는 4 주후, 8주후 모두 유의한 변화가 없었다(p>0.05). 4. FOCQ의 변화는 치료 4주후에는 유의한 차이가 있었으나(p=0.05) 8주 후에는 유의한 차이가 없었다(p=0.13) 5. 뜸치료를 통해 환자에게서 파킨슨병 임상척도의 변화 외에 움직임의 유연성이나, 덜 피로함과 같은 다양한 변화가 나타났다.

Objective : This study was designed to evaluate the effect of moxibustion with various scales on symptoms of idiopathic Parkinson's disease. Methods : Subjects were voluntarily recruited by newspapers and internet. All the subjects are confirmed as idiopathic parkinson's disease by a neurologist. The moxibustion therapy was performed 5 times a week by patient's family at home and once a week by oriental medical doctor at hospital. Moxibustion points were GV2O, CV12, ST36, BL18, BL2O. Intensity was up to pain threshold according to patients not to get burned. The patient's symptoms were assessed before, after 4 weeks and after 8 weeks treatment by unified Parkinson's disease rating scale(UPDRS), modified Hoehn-Yahr(H-Y) stage, Schwab & England activity of daily living and freezing of gait questionnaire(FOGQ). Results : Total UPDRS scores were significantly improved after 4 weeks(p<0.01) and after 8 weeks(p<0.01) compared to the pre-treatment. There were significant changes in H-Y stage after 4 weeks(p<0.05), but there were no significant changes in H-Y stage after 8 weeks. The scores of ADL were not significantly improved after 4 weeks(p>0.05) and after 8 weeks(p>0.05). There were significant changes in FOGQ scale after 4 weeks(p=0.05) and but there were no significant changes in FOGQ scale after 8 weeks(p=0.13). Conclusion : This study suggests that moxibustion treatments can be applicable to improve symptoms in the patients with idiopathic Parkinson's disease.